Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures

Therapeutics and Clinical Risk Management

Volumn 6, Issue 1, 2010, Pages 103-109

  Brown, Martin E ^a   El Mallakh, Rif S ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Epilepsy seizures; Eslicarbazepine; Licarbazepine; Partial onset seizures; Voltage gated sodium channel

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ESLICARBAZEPINE ACETATE; ETHINYLESTRADIOL; ETIRACETAM; EXALIEF; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; STEDESA; TOLBUTAMIDE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; WARFARIN; ZEBINIX;

ACTION POTENTIAL; AREA UNDER THE CURVE; BALANCE DISORDER; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; DIPLOPIA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FOCAL EPILEPSY; HUMAN; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NONHUMAN; PR INTERVAL; REVIEW; SIDE EFFECT; SIMPLE PARTIAL SEIZURE; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; STRUCTURE ANALYSIS; VERTIGO;

EID: 77950838484     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia. 1991;32(4): 429-445.
2. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia. 1993;34(3):453-468.
3. Forsgren L, Beghi E, Oun A, Sillanpaa M. The epidemiology of epilepsy in Europe - a systematic review. Eur J Neurology. 2005;12: 245-253.
4. Birbeck GL Hays RD, Cui XP, Vickrey BG. Seizure Reduction and Quality of Life Improvements in People with Epilepsy. Epilepsia. 2002;43(5):535-538.
5. Wirrell EC. Epilepsy-related Injuries. Epilepsia. 2006;47(Suppl 1): 79-86.
6. Josty IC, Narayanan V, Dickson WA. Burns in patients with epilepsy: changes in epidemiology and implications for burn treatment and prevention. Epilepsia. 2000;41(4):453-456.
7. Hamer HM, Spottke A, Aletsee C, et al. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia. 2006;47(12):2165-2172.
8. Krauss GL, Ampaw L, Krumholz A. Individual state driving restrictions for people with epilepsy in the US. Neurology. 2001;57(10): 1780-1785.
9. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314-319.
10. Faught E. Monotherapy in adults and elderly persons. Neurology. 2007;69(Suppl 3):S3-S9.
11. Almeida L, Falcão A, Maia J, Mazur D, Gellert M, Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol. 2005;45:1062-1066.
12. Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics. 2007;4:88-96.
13. Volosov A, Xiaodong S, Perucca E, Yagen B, Sintov A, Bialer M. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to health Chinese subjects. Clin Pharmacol Ther. 1999;66(6):547-553.
14. Benes J, Parada A, Figueiredo AA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J Med Chem. 1999; 42(14):2582-2587.
15. + channel pharmacology and molecular mechanisms of gating. Curr Pharm Des. 2006; 12(4):429-442.
16. Parada A, Soares-da-Silva P. The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine. Neurochem Int. 2002;40:435-440.
17. Bonifácio MJ, Sheridan RD, Parada A, Cunha RA, Patmore L, Soares-da-Silva P. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia. 2001;42(5):600-608.
18. El-Mallakh RS, Huff MO. Mood stabilizers and ion regulation. Harv Rev Psychiatry. 2001;9:23-32.
19. Araújo IM, Ambrósio AF, Leal EC, et al. Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine, and two new puta-tive antiepileptic drugs, BIA 2-024 and BIA 2-093. Epilepsia. 2004; 45(12):1498-1505.
20. Fontes-Ribeiro C, Nunes T, Falcäo A, et al. Eslicarbazepine acetate (BIA 2-093): Relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200 mg and 800 mg tablet formulations. Drugs R D. 2005;6(5):253-260.
21. Maia J, Vas-da-Silva M, Almeida L, et al. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs R D. 2005;6(4):201-206.
22. Fontes-Ribeiro C, Macedo T, Nunes T, et al. Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, open-label, crossover, single-centre study in healthy volunteers. Drugs R D. 2008;9(6):447-454.
23. Falcão A, Maia J, Almeida L, Mazur D, Gellert M, Soares-da-Silva P. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharm Drug Dispos. 2007;28(5):249-256.
24. Almeida L, Potgieter JL, Maia J, Potgieter MA, Mota F, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol. 2008;64(3):267-273.
25. Almeida L, Soares-da-Silva P. Safety, tolerability and pharmacolokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J Clin Pharmacol. 2004;44:906-918.
26. Maia J, Almeida L, Falcão A, et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther. 2008;46(3):119-120.
27. Alves G, Figueiredo I, Castel-Branco M, et al. Biomed Chromatogr. 2007;21(11):1127-1134.
28. Elger C, Halász P, Maia J, Almeida L, Soares-da-Silva P, BIA-2093-301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double blind, placebo-controlled, parallelgroup phase III study. Epilepsia. 2009;50(3):454-463.
29. European Medicines Agency. CHMP Assessment Report for Exalief: International Nonproprietary Name: eslicarbazepine acetate. London, 19 February 2009 http://www.emea.europa.eu/humandocs/PDFs/EPAR/exalief/H-987-en6.pdf, accessed 13 October 2009.
30. Vas da Silva M, Costa R, Soares E, et al. Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundam Clin Pharmacol. 2009. Epub ahead of print.
31. Rocha JF, Caz-da-Silva M, Almeida L, et al. Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects. Int J Clin Pharmacol Ther. 2009;47(4):255-261.
32. Sierra-Paredes G, Oreiro-García T, Vázquez-Illanes MD, Sierra-Marcuňo G. Effect of eslicarbazepine acetate (BIA 2-093) on latrunculin A-induced seizures and extracellular amino acid concentrations in the rat hippocampus. Epilepsy Res. 2007;77(1):36-42.
33. Sierra-Paredes G, Nú ez-Rodriguez A, Vázquez-López A, Oreiro-García T, Sierra-Marcu o G. Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats. Epilepsy Res. 2006;72(2-3):140-146.
34. Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate: A double-blind, add-on, placebo-controlled, exploratory trial in adult patients with partial-onset seizures. Epilepsia. 2007;48(3):497-504.
35. Almeida L, Minciu I, Nunes T, et al. Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. J Clin Pharmacol. 2008;48(8):966-977.
36. Isojarvi JI, Turkka J, Pakarinen AJ, Kotila M, Rattya J, Myllyla VV. Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy. Epilepsia. 2001;42(7):930-934.
37. Hirfanoglu T, Serdaroglu A, Camurdan O, et al. Thyroid function and volume in epileptic children using carbamazepine, oxcarbazepine and valproate. Pediatrics International. 2007;49(6):822-826.
38. Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia. 2006;47(3):510-515.
39. Cansu A, Yesilkaya E, Serdaroǧlu A, et al. Evaluation of bone turnover in epileptic children using oxcarbazepine. Pediatr Neurol. 2008;39:266-271.
40. Deckers C, Czuczwar S, Hekster Y, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 2000;41(11):1364-1374.
41. Leppik IE. Monotherapy and polypharmacy. Neurology. 2000; 55(11 Suppl 3):S25-S29.